MCRB News and Press, Seres Therapeutics Inc. From 11/02/23

Acushnet Holdings Corp. (GOLF) is expected to report $0.54 for Q3 2023 Paramount Global (PARA) is expected to report $0.09 for Q3 2023 Curis Inc. (CRIS) is expected to report $-2.32 for Q3 2023 Quanta Services Inc. (PWR) is expected to report $1.99 for Q3 2023 GRI Bio Inc. (GRI) i...

Flagship Pioneering Launches Pioneering Intelligence PR Newswire CAMBRIDGE, Mass. , Nov. 1, 2023 /PRNewswire/ -- Flagship Pioneering today launched Pioneering Intelligence, an initiative of Flagship Pioneering harnessing artificial intelligence (AI) to accelerate...

Hitachi Construction Machinery Co. Ltd ADR (HTCMY) is expected to report for Q2 2024 DigitalBridge Group Inc. (DBRG) is expected to report $0 for Q3 2023 LY Corp ADR (YAHOY) is expected to report for Q2 2024 DT Midstream Inc. (DTM) is expected to report $0.9 for Q3 2023 Summit Mat...

Seres Therapeutics Inc. (MCRB) is expected to report $-0.47 for Q3 2023

Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that it will release third quarter 2023 financial results on Thursday, November 2, 2023. Management will host a conference call with investors to discuss the results and corporate updates at 8:00...

2023-10-20 15:00:13 ET More on the markets S&P 500 Will Likely Underperform And 5% Money Markets Are NOT The Answer Equities Climbing A Wall Of Worry (Technical Analysis) SPY: Short-Term Bounce Testing The Downtrends (Technical Analysis) Here is why you s...

Seres Therapeutics, Inc. (Nasdaq: MCRB) today announced multiple abstracts to be presented at IDWeek 2023 in Boston, Massachusetts (October 11-15, 2023), including two posters of post-hoc analyses from the ECOSPOR III and ECOSPOR IV Phase 3 trials, which supported the recent approval by the US ...

2023-09-25 17:15:50 ET Gainers: Pliant Therapeutics ( NASDAQ: PLRX ) +8% . ARS Pharmaceuticals ( SPRY ) +6% . Amylyx Pharmaceuticals ( AMLX ) +4% . Seres Therapeutics ( MCRB ) +2% . Pulmonx Corporation ( LUNG ) +2% . Lo...

Flagship Pioneering Announces Appointment of Amanda Kay as Chief Business Development Officer PR Newswire CAMBRIDGE, Mass. , Sept. 11, 2023 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, announced today the appointment of Amanda K...

2023-09-11 03:47:28 ET Summary Seres Therapeutics launched VOWST for recurrent C. difficile infection in early June, in partnership with Nestle Health. VOWST represents a significant improvement over current standard of care. Considering high efficacy, safety and ease-of administr...